First-in-human trial of CESS®-nanoformed drug on track to begin by end of 2020

Nanoform Finland Plc. (Nanoform; Helsinki, Finland) has announced its initiation of a good manufacturing practice (GMP) campaign for a first-in-human trial of a nano-formed anti-inflammatory drug, made using the company’s proprietary Controlled Expansion of Supercritical Solutions (CESS®) nano-forming technology. The trial represents the progression on Nanoform’s first GMP campaign, which has been initiated in partnership with Quotient Sciences (Nottingham, UK); the trial is on track to begin dosing before the end of 2020 – ahead of initial schedule – and results of the study are now expected before the end of June 2021. The trial will investigate an oral, immediate-release,...